Skip to main content
. 2023 Jun 26;13(11):3675–3688. doi: 10.7150/thno.84118

Figure 3.

Figure 3

In vitro anti-oxidant, anti-apoptosis, and anti-androgen capacities of ZnMOF-MN. A. Cell viability of DPCs treated with 5 μg mL-1 ZnMOF solution, BMN extract, or ZnMOF-MN extract (~6.46 μg mL-1 ZnMOF) for 24 h and then incubated with 3 mM H2O2 for 30 min. B. Cell viability of DPCs treated with 5 μM TPEN and 5 μg mL-1 ZnMOF solution, BMN extract, or ZnMOF-MN extract for 24 h. C-D. Representative images and quantification of dead DPCs stained with PI (red). Cell morphological changes in the bright field (BF) also reflect the cell condition. E-F. Representative images and ratio of apoptotic cells measured by flow cytometer. G. RT-qPCR analysis of DDK1, CCND1, AMER3, LEF1, HSD17B2, SRD5A1, Caspase-3, and Caspase-9 in DPCs treated with 100 μM DHT and 20 μM curcumin, 2.5 μg mL-1 ZnMOF, BMN extract, or ZnMOF-MN extract (~3.23 μg mL-1 ZnMOF) for 24 h. RQ values (relative quantitative value to the internal reference) of DPCs treated with 100 μM DHT and BMN extract were compared with the control group (Ctrl, 0.1% DMSO) while that of DPCs treated with 20 μM curcumin, 2.5 μg mL-1 ZnMOF, and ZnMOF-MN extract were compared with the DHT group. n=3; *p < 0.05 vs. Ctrl in A-C; #p < 0.05 vs. Ctrl, *p < 0.05 vs. DHT in G.